Fintel on MSN8h
Cantor Fitzgerald Initiates Coverage of Protara Therapeutics (TARA) with Overweight RecommendationFintel reports that on March 14, 2025, Cantor Fitzgerald initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a ...
Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from ...
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases ...
Fintel on MSN3d
LifeSci Capital Initiates Coverage of Protara Therapeutics (TARA) with Outperform RecommendationFintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a ...
Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs ...
Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline ...
News Medical on MSN1d
How gut health shapes heart disease risk — and what you can do about itA new review highlights how gut microbiome imbalances contribute to cardiovascular disease by altering short-chain fatty ...
Its candidate UNR844 (lipoic acid/choline ester chloride) – acquired with Encore Vision in 2017 – works by restoring the elasticity of the lens.
Its candidate UNR844 (lipoic acid/choline ester chloride) – acquired with Encore Vision in 2017 – works by restoring the elasticity of the lens. Neurotech Pharma's cell therapy Encelto has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback